Alivus Life Sciences FY 2025‑26: Strong Results, Dividend, and Growth Outlook
Alivus Life Sciences FY 2025‑26: audited results, dividend recommendation, and global API strategy show solid growth and shareholder value.
- Alivus Life Sciences Limited
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read